C Wiblin
Overview
Explore the profile of C Wiblin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hallis B, Silman N, Noonan S, Baker R, Roberts A, Quinn C, et al.
Dev Biol (Basel)
. 2003 Apr;
111:321-6.
PMID: 12678256
The characterisation and evaluation of the UK licensed human anthrax vaccine depends on several in vivo tests that determine its safety and potency. Assays for the determination of functionally active...
2.
Skinner G, Fink C, Melling J, Wiblin C, Thornton B, Hallworth J, et al.
Med Microbiol Immunol
. 1992 Jan;
180(6):305-20.
PMID: 1549071
Three hundred and forty-seven subjects at risk for herpes genitalis were vaccinated with Skinner vaccine, NFUAc.HSV1.(S-MRC5), and were followed for an average duration of 2 years representing a total consortship...
3.
Skinner G, Fink C, Cowan M, Buchan A, Fuller A, Hartley C, et al.
Med Microbiol Immunol
. 1987 Jan;
176(3):161-8.
PMID: 3037289
Fifty subjects at risk of herpes genitalis received 109 immunizations with Skinner herpes vaccine and were assessed after a follow-up period of 4-48 months, representing a total follow-up period of...
4.
Muniu E, Durham J, Shariff D, Hartley C, Fuller A, Melling J, et al.
Med Microbiol Immunol
. 1987 Jan;
176(6):315-27.
PMID: 2828898
Antibody reactivity against herpes simplex virus (HSV) was investigated in 15 subjects who received three subcutaneous immunisations with Skinner HSV vaccine. Humoral antibody responses were detected against type 1 HSV...
5.
Buchan A, Skinner G, Fuller A, Hartley C, Hallworth J, Stocker D, et al.
Vaccine
. 1985 Mar;
3(1):49-53.
PMID: 4002836
The apparent increasing incidence of herpes simplex virus infections of the genital tract has focused attention on the efficacy of vaccination in preventing infection or modifying established disease. Results of...
6.
Woodman C, Buchan A, Fuller A, Hartley C, Skinner G, Stocker D, et al.
Br J Vener Dis
. 1983 Oct;
59(5):311-3.
PMID: 6311322
A subunit antigenoid vaccine, Ac NFU1 (S-) MRC 5, was used in patients who had had a clinical episode of herpes genitalis. The rate of recurrence was compared with that...
7.
Skinner G, Woodman C, Hartley C, Buchan A, Fuller A, Durham J, et al.
Br J Vener Dis
. 1982 Dec;
58(6):381-6.
PMID: 6293640
A subunit antigenoid vaccine, Ac NFU1 (S-) MRC, was used to prevent primary herpes genitalis in 60 subjects considered to be at risk of this infection. There was no evidence...
8.
Skinner G, Woodman C, Hartley C, Buchan A, Fuller A, Wiblin C, et al.
Dev Biol Stand
. 1982 Jan;
52:333-44.
PMID: 6299842
The preparation and early clinical experience with "antigenoid" vaccine Ac NFU1(S-) MRC is described. A neutralising antibody response against both type 1 and type 2 herpes simplex virus was stimulated...